Identification of Tumor-Suppressive


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Mar 2022
Historique:
received: 19 01 2022
revised: 13 03 2022
accepted: 28 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

Recently, our studies revealed that some passenger strands of microRNAs (miRNAs) were closely involved in cancer pathogenesis. Analysis of miRNA expression signatures showed that the expression of miR-30e-3p (the passenger strand of pre-miR-30e) was significantly downregulated in cancer tissues. In this study, we focused on miR-30e-3p (the passenger strand of pre-miR-30e). We addressed target genes controlled by miR-30e-3p that were closely associated with the molecular pathogenesis of head and neck squamous cell carcinoma (HNSCC). Ectopic expression assays demonstrated that the expression of miR-30e-3p attenuated cancer cell malignant phenotypes (e.g., cell proliferation, migration, and invasive abilities). Our analysis of miR-30e-3p targets revealed that 11 genes (ADA, CPNE8, C14orf126, ERGIC2, HMGA2, PLS3, PSMD10, RALB, SERPINE1, SFXN1, and TMEM87B) were expressed at high levels in HNSCC patients. Moreover, they significantly predicted the short survival of HNSCC patients based on 5-year overall survival rates (p < 0.05) in The Cancer Genome Atlas (TCGA). Among these targets, SERPINE1 was found to be an independent prognostic factor for patient survival (multivariate Cox regression; hazard ratio = 1.6078, p < 0.05). Aberrant expression of SERPINE1 was observed in HNSCC clinical samples by immunohistochemical analysis. Functional assays by targeting SERPINE1 expression revealed that the malignant phenotypes (e.g., proliferation, migration, and invasion abilities) of HNSCC cells were suppressed by the silencing of SERPINE1 expression. Our miRNA-based approach will accelerate our understanding of the molecular pathogenesis of HNSCC.

Identifiants

pubmed: 35409173
pii: ijms23073808
doi: 10.3390/ijms23073808
pmc: PMC8998321
pii:
doi:

Substances chimiques

CPNE8 protein, human 0
Carrier Proteins 0
MicroRNAs 0
PSMD10 protein, human 0
Plasminogen Activator Inhibitor 1 0
Proto-Oncogene Proteins 0
SERPINE1 protein, human 0
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : JSPS KAKENHI
ID : 19H03847
Organisme : JSPS KAKENHI
ID : 20H03883
Organisme : JSPS KAKENHI
ID : 21K09577

Références

Cancer Metastasis Rev. 2017 Sep;36(3):525-545
pubmed: 28836104
Head Neck. 2019 Feb;41(2):429-439
pubmed: 30548470
Biochim Biophys Acta Gene Regul Mech. 2020 Jun;1863(6):194417
pubmed: 31493559
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
J Hum Genet. 2020 Nov;65(11):1019-1034
pubmed: 32623445
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cells. 2020 Sep 11;9(9):
pubmed: 32932948
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Ann Transl Med. 2018 May;6(9):166
pubmed: 29911114
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2019 May 1;25(9):2860-2873
pubmed: 30723145
Head Neck. 2021 Feb;43(2):645-667
pubmed: 33159410
Int J Mol Sci. 2021 Jun 08;22(12):
pubmed: 34201353
Oncol Lett. 2019 Feb;17(2):2393-2399
pubmed: 30675305
Biomedicines. 2021 Dec 11;9(12):
pubmed: 34944699
Int J Mol Sci. 2021 Sep 13;22(18):
pubmed: 34576039
Genes (Basel). 2021 Nov 27;12(12):
pubmed: 34946859
Anticancer Res. 2021 Oct;41(10):4821-4836
pubmed: 34593431
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683
pubmed: 31189965
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Cancer Res. 2020 Apr 15;80(8):1720-1734
pubmed: 32015093
Cancers (Basel). 2020 Sep 23;12(10):
pubmed: 32977589
Front Oncol. 2020 Dec 21;10:544476
pubmed: 33680908
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Int J Mol Sci. 2021 Sep 14;22(18):
pubmed: 34576110
Nat Rev Clin Oncol. 2018 Sep;15(9):541-563
pubmed: 29784926
Biomedicines. 2020 Dec 12;8(12):
pubmed: 33322675
Nat Rev Genet. 2011 Nov 18;12(12):861-74
pubmed: 22094949
Int J Cancer. 2015 Jun 1;136(11):2515-23
pubmed: 25111594
Nat Commun. 2020 Feb 20;11(1):968
pubmed: 32080184
Oncotarget. 2016 Aug 30;7(35):57351-57366
pubmed: 27385000
Nat Rev Cancer. 2018 Jan;18(1):5-18
pubmed: 29170536
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Cancer Metastasis Rev. 2019 Sep;38(3):483-492
pubmed: 31734763
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Oncol Lett. 2021 Jan;21(1):11
pubmed: 33240417
Pharmacol Rev. 2018 Jan;70(1):1-11
pubmed: 29196555
J Hum Genet. 2021 May;66(5):519-534
pubmed: 33177704
Int J Oncol. 2018 Jan;52(1):166-178
pubmed: 29115582
Mol Cell Biol. 2021 May 21;41(6):e0056520
pubmed: 33820852
Anticancer Res. 2011 Sep;31(9):2683-92
pubmed: 21868508
Ann Surg Oncol. 2014 Oct;21(11):3680-90
pubmed: 24217791
Am J Transl Res. 2021 Apr 15;13(4):2256-2269
pubmed: 34017387
Biomed Pharmacother. 2018 Sep;105:83-94
pubmed: 29852393
Tumour Biol. 2017 Mar;39(3):1010428317692204
pubmed: 28347244
Mol Oncol. 2020 Feb;14(2):426-446
pubmed: 31755218
J Cell Physiol. 2012 Feb;227(2):493-507
pubmed: 21465481
Nucleic Acids Res. 1989 Jun 12;17(11):4380
pubmed: 2662142
Gene. 1998 Aug 17;216(1):113-22
pubmed: 9714768
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Cell Mol Life Sci. 2021 Jul;78(13):5275-5301
pubmed: 34023917
Curr Biol. 2006 Dec 19;16(24):2385-94
pubmed: 17174914
Int J Mol Sci. 2021 Nov 24;22(23):
pubmed: 34884487
Am J Transl Res. 2018 Jul 15;10(7):1949-1960
pubmed: 30093934
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899691
Oncotarget. 2015 Oct 6;6(30):29016-33
pubmed: 26359694
EMBO Rep. 2003 Aug;4(8):800-6
pubmed: 12856001
Cancer Sci. 2020 Feb;111(2):356-368
pubmed: 31778279
Oncol Lett. 2017 Apr;13(4):2053-2058
pubmed: 28454361
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138313
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Chikashi Minemura (C)

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Department of Oral and Maxillofacial Surgery, National Defense Medical College Hospital, Tokorozawa 359-8513, Japan.

Shunichi Asai (S)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Ayaka Koma (A)

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Ikuko Kase-Kato (I)

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Nozomi Tanaka (N)

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Naoko Kikkawa (N)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Atsushi Kasamatsu (A)

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Hidetaka Yokoe (H)

Department of Oral and Maxillofacial Surgery, National Defense Medical College Hospital, Tokorozawa 359-8513, Japan.

Toyoyuki Hanazawa (T)

Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Katsuhiro Uzawa (K)

Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Naohiko Seki (N)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH